A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis

Respiratory Medicine

Volumn 98, Issue 8, 2004, Pages 697-707

  Sethi, S ^a   Fogarty, C ^b   Fulambarker, A ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Spartanburg Pharmaceutical Research ^*  (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Acute exacerbation of chronic bronchitis; Clinical trial; Gemifloxacin; Levofloxacin; Respiratory tract infection

Indexed keywords

GEMIFLOXACIN; LEVOFLOXACIN; OXYGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; STEROID;

ADULT; ARTICLE; BACTERIUM CULTURE; CHRONIC BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; ECG ABNORMALITY; ERYTHEMA; FEMALE; FISHER EXACT TEST; FOLLOW UP; GERMANY; HUMAN; HYPESTHESIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SPUTUM CULTURE; STATISTICAL SIGNIFICANCE; TENDINITIS; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; BRONCHITIS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; OFLOXACIN; TREATMENT OUTCOME;

EID: 3042551134     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.03.028     Document Type: Article

References (27)

1. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations Chest 108 1995 43S-52S
2. Mannino D.M. Homa D.M. Akinbami L.J. Ford E.S. Redd S.C. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000 Respir Care 47 2002 1184-1189
3. Niederman M.S. McCombs J.S. Linger A.N. Kumar A. Popovian R. Treatment cost of acute exacerbations of chronic bronchitis Clin Ther 21 1999 576-591
4. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, and the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
5. Felmingham D. Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander Project 1992-1996 J Chemother 11 Suppl 1 1999 5-21
6. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management J Antimicrob Chemother 43 Suppl A 1999 97-105
7. Grossman R.F. Cost-effective therapy for acute exacerbation of chronic bronchitis Semin Respir Infect 15 2000 71-81
8. Heaton V.J. Ambler J.E. Fisher L.M. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro Antimicrob Agents Chemother 44 2000 3112-3117
9. Rittenhouse S. McCloskey L. Broskey J. et-al In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens J Antimicrob Chemother 45 Suppl S1 2000 23-27
10. McCloskey L. Moore T. Niconovich N. et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA J Antimicrob Chemother 45 Suppl S1 2000 13-21
11. Biedenbach D.J. Jones R.N. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program Diagn Microbiol Infect Dis 46 2003 55-61
12. National Committee for Clinical Laboratory Standards. Performance Standards, for Antimicrobial Susceptibility Testing-Eighth Informational Supplement Approved Standard M100-S8. Wayne, PA: NCCLS; 1998.
13. Makuch R. Simon R. Sample size requirements for evaluating a conservative therapy Cancer Treat Rep 62 1978 1037-1040
14. Wilson R. Langan C. Ball P. Bateman K. Pypstra R. Gemifloxacin 2 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis Respir Med 97 2003 242-249
15. Wilson R. Schentag J.J. Ball P. Mandell L. 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes Clin Ther 24 2002 639-652
16. Ball P. Wilson R. Mandell L. Brown J. Henkel T. 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin J Chemother 13 2001 288-298
17. Blondeau J. A review of clinical trials with fluoroquinolones with an emphasis on new agents Exp Opin Invest Drugs 9 2000 383-413
18. Koeth L.M. Jacobs M.R. Bajaksouzian S. Zilles A. Lin G. Appelbaum P.C. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000 Int J Antimicrob Agents 19 2002 33-37
19. Jones R.N. Biedenbach D.J. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001) Diagn Microbiol Infect Dis 45 2003 273-278
20. Gemifloxacin (Factive ®). Prescribing Information July, 2003. South San Francisco, CA: Oscient Pharmaceuticals, Waltham, MA USA, 2003.
21. Zhanel G.G. Palatnick L. Nichol K.A. Bellyou T. Low D.E. Hoban D.J. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrob Agents Chemother 47 2003 1867-1874
22. Karlowsky J.A. Draghi D.C. Thornsberry C. Jones M.E. Critchley I.A. Sahm D.F. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US Int J Antimicrob Agents 20 2002 76-85
23. Davidson R. Cavalcanti R. Brunton J.L. et al Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 346 2002 520-521
24. Urban C. Rahman N. Zhao X.L. et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy J Infect Dis 184 2001 794-798
25. Nazir J, Urban C, Mariano N, Burns J, Segal-Maurer S, Rahal JJ. Levofloxacin resistant Haemophilus influenzae in a long-term care facility. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, September 27-30, 2002. p. 96, Abstract C2-647.
26. Anderson K.B. Tan J.S. File T.M. Jr DiPersio J.R. Willey B.M. Low D.E. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia Clin Infect Dis 37 2003 376-381
27. Zhao X. Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis 33 Suppl 3 2001 S147-S156